| 2026-03-31 |
详情>>
股本变动：
变动后总股本14006.83万股
|
| 2026-03-31 |
详情>>
业绩披露：
2025年年报每股收益0.04美元,归母净利润497.30万美元,同比去年增长130.23%
|
| 2026-03-31 |
财报披露：
美东时间 2026-03-31 盘前发布财报
|
| 2026-02-15 |
详情>>
内部人交易：
Schallenberger Mark A.股份减少7709.00股
|
| 2025-11-10 |
详情>>
业绩披露：
2025年三季报(累计)每股收益0.04美元,归母净利润491.60万美元,同比去年增长137.01%
|
| 2025-09-15 |
股东大会：
将于2025-11-07召开股东大会
会议内容 ▼▲
- 1.To elect the six nominees named in the accompanying proxy statement to serve as directors until the next annual meeting of stockholders and until their respective successors have been duly elected and qualified;
2.To ratify the appointment of Grant Thornton LLP as our independent registered public accounting firm for the year ending December 31, 2025;
3.To approve an amendment to the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan to increase the number of shares available under the plan by 12,300,000 shares;
4.To approve, on an advisory (non-binding) basis, the compensation of our executive officers named in the accompanying proxy statement;
5.To approve, on an advisory (non-binding) basis, the frequency of future advisory votes on executive compensation;
6.To transact such other business as may properly be brought before the Annual Meeting and any adjournment or postponement thereof.
|
| 2025-08-12 |
详情>>
业绩披露：
2025年中报每股收益0.03美元,归母净利润360.80万美元,同比去年增长143.68%
|
| 2025-05-12 |
详情>>
业绩披露：
2025年一季报每股收益0.00美元,归母净利润5.80万美元,同比去年增长101.32%
|
| 2025-03-06 |
详情>>
业绩披露：
2024年年报每股收益-0.12美元,归母净利润-1644.9万美元,同比去年增长-2592.27%
|
| 2024-11-12 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-0.1美元,归母净利润-1328.4万美元,同比去年增长-367.66%
|
| 2024-08-08 |
详情>>
业绩披露：
2024年中报每股收益-0.06美元,归母净利润-826.1万美元,同比去年增长-93.56%
|
| 2024-06-10 |
股东大会：
将于2024-07-23召开股东大会
会议内容 ▼▲
- 1.To elect the six nominees named in the accompanying proxy statement to serve as directors until the next annual meeting of stockholders and until their respective successors have been duly elected and qualified;
2.To ratify the appointment of Grant Thornton LLP as our independent registered public accounting firm for the year ending December 31, 2024;
3.To approve, on an advisory basis, the compensation of our executive officers named in the accompanying proxy statement;
4.To transact such other business as may properly be brought before the Annual Meeting and any adjournment or postponement thereof.
|
| 2024-05-15 |
详情>>
业绩披露：
2024年一季报每股收益-0.03美元,归母净利润-440万美元,同比去年增长-111.74%
|
| 2024-04-01 |
详情>>
业绩披露：
2023年年报每股收益0.01美元,归母净利润66.00万美元,同比去年增长107.78%
|
| 2023-11-14 |
详情>>
业绩披露：
2023年三季报(累计)每股收益0.04美元,归母净利润496.30万美元,同比去年增长179.08%
|
| 2023-06-08 |
股东大会：
将于2023-07-26召开股东大会
会议内容 ▼▲
- 1.To elect the six nominees named in the accompanying proxy statement to serve as directors until the next annual meeting of stockholders and until their respective successors have been duly elected and qualified;
2.To ratify the appointment of Plante & Moran, PLLC as our independent registered public accounting firm for the year ending December 31, 2023;
3.To approve, on an advisory basis, the compensation of our executive officers named in the accompanying proxy statement;
4.To approve an amendment to our Amended and Restated Certificate of Incorporation, as amended, to require a supermajority director vote to fix the number of directors at more than seven;
5.To approve an amendment to our Amended and Restated Certificate of Incorporation, as amended, to eliminate or limit the personal liability of officers to the extent permitted by recent amendments to the Delaware General Corporation Law;
6.To approve an amendment to our Amended and Restated Certificate of Incorporation, as amended, to amend the exclusive forum provision;
7.To approve the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan;
8.To transact such other business as may properly be brought before the Annual Meeting and any adjournment or postponement thereof.
|
| 2023-03-01 |
复牌提示：
2023-03-01 08:49:20 停牌，复牌日期 2023-03-01 09:40:00
|
| 2022-09-20 |
股东大会：
将于2022-10-26召开股东大会
会议内容 ▼▲
- 1.To elect the six nominees named in the accompanying proxy statement to serve as directors of the Company until the next annual meeting of stockholders and until their respective successors have been duly elected and qualified;
2.To ratify the appointment of Plante & Moran, PLLC (“Plante Moran”) as the Company’s independent registered public accounting firm for the year ending December 31, 2022;
3.To approve, on an advisory basis, the compensation of the Company’s executive officers named in the accompanying proxy statement;
4.To approve the Xtant Medical Holdings, Inc. Second Amended and Restated 2018 Equity Incentive Plan;
5.To transact such other business as may properly be brought before the Annual Meeting and any adjournment or postponement thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-06-14 |
股东大会：
将于2021-07-27召开股东大会
会议内容 ▼▲
- 1.To elect the six nominees named in the accompanying proxy statement to serve as directors of the Company until the next annual meeting of stockholders and until their respective successors have been duly elected and qualified;
2.To ratify the appointment of Plante & Moran, PLLC (“Plante Moran”) as the Company’s independent registered public accounting firm for the year ending December 31, 2021;
3.To approve, on an advisory basis, the compensation of the Company’s executive officers named in the accompanying proxy statement;
4.To transact such other business as may properly be brought before the Annual Meeting and any adjournment or postponement thereof.
|
| 2020-09-10 |
股东大会：
将于2020-10-27召开股东大会
会议内容 ▼▲
- 1.To elect the six nominees named in the accompanying proxy statement to serve as directors of the Company until the next annual meeting of stockholders and until their respective successors have been duly elected and qualified;
2.To ratify the appointment of Plante & Moran, PLLC as the Company’s independent registered public accounting firm for the year ending December 31, 2020;
3.To approve the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan;
4.To approve, on an advisory basis, the compensation of the Company’s executive officers named in the accompanying proxy statement;
5.To transact such other business as may properly be brought before the Annual Meeting and any adjournment or postponement thereof.
|
| 2019-09-20 |
股东大会：
将于2019-10-30召开股东大会
会议内容 ▼▲
- 1.To elect the five nominees named in the accompanying proxy statement to serve as directors of the Company until the next annual meeting of stockholders and until their respective successors have been duly elected and qualified;
2.To ratify the appointment of Plante & Moran PLLC as the Company’s independent registered public accounting firm for the year ending December 31, 2019;
3.To approve an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 50,000,000 to 75,000,000;
4.To approve an amendment to the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan to increase the number of shares of common stock available for issuance by 1,500,000;
5.To approve, on an advisory basis, the compensation of the Company’s executive officers named in the accompanying proxy statement;
6.To indicate, on an advisory basis, whether future votes to approve executive compensation should occur every one, two, or three years;
7.To transact such other business as may properly be brought before the Annual Meeting and any adjournment or postponement thereof.
|
| 2018-06-26 |
股东大会：
将于2018-08-01召开股东大会
会议内容 ▼▲
- 1.To elect the six directors named in the accompanying proxy statement to serve on the Company’s Board of Directors until the next annual meeting of stockholders and until their respective successors have been duly elected and qualified;
2.To ratify the appointment of EKS&H LLLP as the Company’s independent registered public accounting firm for the year ending December 31, 2018;
3.To approve the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan;
4.To transact such other business as may properly be brought before the Annual Meeting and any adjournment or postponement thereof.
|
| 2018-02-02 |
详情>>
拆分方案：
每12.0000合并分成1.0000股
|
| 2018-01-22 |
股东大会：
将于2018-02-13召开股东大会
会议内容 ▼▲
- 1.To approve the issuance of shares of Common Stock for purposes of Sections 713(a) and 713(b) of the NYSE American Company Guide;
2.To approve an amendment to our certificate of incorporation to effect a reverse stock split of the Common Stock at a ratio of 1:12, to change the number of authorized shares of Common Stock and preferred stock available for issuance and to make such other changes as are described in the enclosed Proxy Statement, as requested by the Investors pursuant to the Restructuring Agreement;
3.To elect six (6) directors named in the accompanying Proxy Statement effective on the closing of the Transactions to serve on the Company’s Board of Directors until their respective successors have been duly elected and qualified;
4.To approve an adjournment of the meeting, if necessary or appropriate, to solicit additional proxies in favor of the foregoing Proposals;
5.To transact such other business as may properly be brought before the Special Meeting and any adjournment or postponement thereof.
|
| 2017-12-08 |
股东大会：
将于2017-12-29召开股东大会
会议内容 ▼▲
- 1.To elect the two Class III directors named in the accompanying Proxy Statement to serve on the Company’s Board of Directors for three year terms until the 2020 Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified;
2.To ratify the appointment of EKS&H LLLP as the Company’s independent registered public accounting firm for the year ending December 31, 2017;
3.To transact such other business as may properly be brought before the Annual Meeting and any adjournment or postponement thereof.
|
| 2016-05-26 |
股东大会：
将于2016-06-15召开股东大会
会议内容 ▼▲
- 1.To elect the three Class II directors named in the accompanying Proxy Statement to serve on the Company’s Board of Directors for three year terms until the 2019 Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified;
2.To ratify the appointment of EKS&H LLLP as the Company’s independent registered public accounting firm for the year ending December 31, 2016;
3.To approve the First Amendment to the Amended and Restated Xtant Medical Equity Incentive Plan (the “Plan”) to increase the number of shares of common stock authorized for issuance under the Plan from 1,400,000 shares to 1,900,000 shares;
4.To conduct an advisory vote to approve the compensation of the named executive officers;
5.To transact such other business as may properly be brought before the Annual Meeting and any adjournment or postponement thereof.
|